ArticleClinical epigenetics2026
Epigenomic subtypes and prognostic methylation signatures in clear cell renal cell carcinoma.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) is characterized by marked epigenetic dysregulation, contributing to aberrant gene expression and tumor progression. To expand current knowledge on genome-wide methylation patterns in ccRCC, we performed Methylated DNA Immunoprecipitation sequencing (MeDIP-seq) on tumor samples from 116 ccRCC patients and 34 adjacent normal renal tissues. We identified differentially methylated regions (DMRs) and integrated these findings with genome-wide copy number alterations.
resultsccRCC tumors exhibited global hypomethylation combined with focal hypermethylation, particularly within intergenic and repetitive genomic regions. Unsupervised clustering revealed three distinct subtypes, including one subtype characterized by chromosomal instability, synchronous metastasis, and poor survival outcomes. We developed a novel methylation score (MethScore), based on hypermethylated regions, which strongly correlated with disease stage and independently predicted overall survival beyond age and clinical stage. Notably, high methylation levels of specific DMRs were linked to recurrence and advanced disease. Validation with TCGA Kidney Renal Clear Cell Carcinoma methylation data supported the prognostic value of these hypermethylated regions. Additionally, MeDIP-seq accurately detected critical copy number alterations, particularly chromosome 3p loss, which were found in 88% of tumors.
conclusionsTogether, our findings demonstrate that genome-wide methylation profiling can resolve clinically relevant ccRCC subtypes, uncover novel biomarkers of disease aggressiveness, and improve patient risk stratification beyond current clinical models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.